. Effect of phorbol esters on Ca 2ϩ sensitivity and myosin light-chain phosphorylation in airway smooth muscle. Am. J. Physiol. 274 (Cell Physiol. 43): C1253-C1260, 1998.-We studied in ␤-escin-permeabilized canine tracheal smooth muscle (CTSM) the effect of the protein kinase C (PKC) agonist phorbol 12,13-dibutyrate (PDBu) on isometric force at a constant submaximal Ca 2ϩ concentration (i.e., the effect on Ca 2ϩ sensitivity) and regulatory myosin light-chain (rMLC) phosphorylation. PDBu increased Ca 2ϩ sensitivity, an increase associated with a concentration-dependent, sustained increase in rMLC phosphorylation. PDBu altered the relationship between rMLC phosphorylation and isometric force such that the increase in isometric force was less than that expected for the increase in rMLC phosphorylation observed. The effect of four PKC inhibitors [calphostin C, chelerythrine chloride, a pseudosubstrate inhibitor for PKC, PKC peptide-(19-31) (PSSI), and staurosporine] on PDBu-induced Ca 2ϩ sensitization as well as the effect of calphostin C and PSSI on rMLC phosphorylation were determined. Whereas none of these compounds prevented or reversed the PDBu-induced increase in Ca 2ϩ sensitivity, the PDBu-induced increase in rMLC phosphorylation was inhibited. We conclude that PDBu increases rMLC phosphorylation by activation of PKC but that the associated PDBu-induced increases in Ca 2ϩ sensitivity are mediated by mechanisms other than activation of PKC in permeabilized airway smooth muscle.
IN AIRWAY SMOOTH MUSCLE, contraction in response to physiological agonists is associated with an increase in cytosolic Ca 2ϩ concentration ([Ca 2ϩ ] i ). The binding of Ca 2ϩ to calmodulin increases myosin light-chain kinase (MLCK) activity and phosphorylation of the 20-kDa regulatory myosin light chain (rMLC) at the serine-19 and threonine-18 residues. rMLC phosphorylation at these sites allows the binding of myosin to actin, which increases actomyosin Mg 2ϩ -ATPase activity. However, smooth muscle contraction is not only regulated by [Ca 2ϩ ] i , since membrane receptor stimulation increases isometric force developed at a constant submaximal [Ca 2ϩ ] i , i.e., increases Ca 2ϩ sensitivity (25) .
In addition to GTP-binding proteins (10, 21) , there is evidence in vascular (18) and colonic (27) smooth muscle that protein kinase C (PKC) mediates agonistinduced increases in Ca 2ϩ sensitivity. The role of PKC is controversial, with results depending on the species, the type of smooth muscle, and the membrane receptor agonist studied. Data obtained in permeabilized nonvascular smooth muscle preparations have failed to demonstrate an involvement of PKC in this signal transduction (10, 26) . In permeabilized canine trachea smooth muscle (CTSM), both the phorbol ester phorbol 12,13-dibutyrate (PDBu), a PKC agonist, and the muscarinic receptor agonist acetylcholine (ACh) increase Ca 2ϩ sensitivity (4) . Of interest, in permeabilized CTSM, pharmacological PKC inhibitors do not attenuate AChinduced increases in isometric force at a constant submaximal [Ca 2ϩ ], indicating that PKC does not mediate ACh-induced increases in Ca 2ϩ sensitivity (5) .
The purpose of the current study was to elucidate the mechanism by which PDBu increases Ca 2ϩ sensitivity in airway smooth muscle. We used a ␤-escin-permeabilized CTSM preparation in which the [Ca 2ϩ ] at the contractile apparatus can be controlled by manipulating the [Ca 2ϩ ] in solutions bathing the muscle, yet intracellular second messenger systems, including PKC, remain intact (3) . We studied the effect of PDBu and four pharmacological PKC inhibitors, calphostin C, chelerythrine chloride, a PKC pseudosubstrate inhibitor [PKC peptide-(19-31) (PSSI)], and staurosporine, on isometric force and rMLC phosphorylation at constant submaximal [Ca 2ϩ ]. Isometric force measurements. Muscle strips (width, 0.1-0.2 mm; length, 3-5 mm; wet weight, 0.05-0.1 mg) were mounted in 0.1-ml cuvettes and continuously superfused at 2 ml/min with PSS (37°C) aerated with 94% O 2 -6% CO 2 , providing a pH of ϳ7.4, PO 2 of ϳ400 mmHg, and PCO 2 of ϳ39 mmHg in the PSS. One end of the strips was anchored via stainless steel microforceps to a stationary metal rod and the other end via stainless steel microforceps to a calibrated force transducer (model KG4, Scientific Instruments, Heidelberg, Germany). Optimal length of each strip was achieved as previously described (3, 4) .
MATERIALS AND METHODS

Experimental Techniques
Permeabilization procedure and normalization of the isometric force measurements. Muscle strips were permeabilized with 100 µM ␤-escin for 20 min at 25°C in Ca 2ϩ -free relaxing solution according to a previously described protocol (3). The composition of the relaxing solution was as follows (3): 7.5 mM MgATP, 4 mM EGTA, 20 mM imidazole, 1 mM dithiothreitol (DTT), 1 mM free Mg 2ϩ , 1 nM free Ca 2ϩ , 10 mM creatinine phosphate, and 0.1 mg/ml creatine phosphokinase. The pH was buffered to 7.0 at 25°C with KOH, and ionic strength was kept constant at 0.2 M by adjusting the concentration of potassium acetate. All experimental solutions contained the Ca 2ϩ ionophore A-23187 (10 µM) to deplete sarcoplasmic reticulum Ca 2ϩ stores, and all experimental protocols were performed at 25°C. Before the experimental protocols were started, the maximal contractile response for each strip was determined by exposure to 10 µM free Ca 2ϩ ; all subsequent isometric force measurements were normalized to this response.
rMLC phosphorylation measurements. rMLC phosphorylation was measured in separate sets of permeabilized CTSM strips (width, 0.1-0.2 mm; length, 10-15 mm; wet weight, 0.1-0.15 mg). After an equilibration period of 30 min in aerated PSS at 25°C, the strips were incubated in Ca 2ϩ -free PSS containing 2mM EGTA for 15 min. Then, intracellular Ca 2ϩ stores were depleted by exposing the strips to 100 µM ACh for 10 min. ACh was removed from the bath by exchanging solutions repeatedly with Ca 2ϩ -free PSS over 15 min before tissues were permeabilized. After experimental interventions, muscle strips were flash-frozen by rapid immersion in acetone containing 10% trichloroacedic acid (TCA) and 10 mM DTT cooled to Ϫ80°C with crushed dry ice. rMLC was extracted as described by Gunst et al. (15) . Proteins were separated by glycerol-urea polyacrylamide gel (10% acrylamide-0.5% bis-acrylamide) electrophoresis. All gels were subjected to preelectrophoresis for 1 h at 400 V (10°C) to remove urea and to allow DTT and thioglycolate to enter the gels. Electrophoresis was conducted for 1 h at 100 V and then for 17 h at 400 V (10°C). Proteins were transferred to nitrocellulose membrane (0.2 µm) for 4 h at 1.6 A (15°C). Nitrocellulose sheets were washed two times with 10 mM Tris-buffered saline containing 5% (wt/vol) BSA for 1 h before labeling rMLC with polyclonal affinity-purified rabbit anti-rMLC antibody (15) . The anti-rMLC antibody was detected with 125 Ilabeled protein A (DuPont, Boston, MA). The unphosphorylated and phosphorylated bands of rMLC were visualized by phosphorimage analysis (PhosphorImager, Molecular Dynamics, Sunnyvale, CA), and fractional phosphorylation was quantified by ImageQuaNT software (Molecular Dynamics). After local background subtraction, fractional phosphorylation was calculated as the ratio of the sum of mono-and diphosphorylated rMLC to total rMLC.
Experimental Protocols
Four different experimental protocols were conducted using tissue obtained from separate groups of animals.
Time-dependent effect of PDBu on rMLC phosphorylation. This protocol was conducted to establish the time course of PDBu's effect on changes in rMLC phosphorylation at a constant submaximal [Ca 2ϩ ]. In preliminary studies, we confirmed that increases in rMLC phosphorylation produced by solutions containing 0.3 µM free Ca 2ϩ alone are stable over 25 min (data not shown). Nine permeabilized CTSM strips were prepared from each of five dogs. One strip was not stimulated and was flash-frozen in relaxing solution for baseline rMLC phosphorylation measurements. Two strips were exposed to 0.3 µM free Ca 2ϩ alone for 10 or 25 min before freezing. The remaining six strips were first exposed to 0.3 µM free Ca 2ϩ alone for 10 min and then to 0.3 µM free Ca 2ϩ containing 1 µM PDBu and flash-frozen at the following time points: 0.5, 1, 2, 5, 10, and 15 min. Free Ca 2ϩ at 0.3 µM produces ϳ10% of maximal isometric force induced by 10 µM free Ca 2ϩ in this preparation, and 1 µM PDBu produces ϳ90% of its maximal effect on isometric force at a constant 0.3 µM free Ca 2ϩ (4) . The time course of PDBu's effect on rMLC phosphorylation was investigated to determine the appropriate time point with the highest rMLC phosphorylation values to freeze the stimulated muscle in subsequent studies.
Concentration-dependent effect of PDBu on rMLC phosphorylation. This protocol determined the effect of various PDBu concentrations on rMLC phosphorylation at 0.3 µM free Ca 2ϩ . In ␤-escin-permeabilized CTSM strips, PDBu (0.001-3 µM) causes a concentration-dependent increase in isometric force at 0.3 µM free Ca 2ϩ (4) . Five permeabilized strips were prepared from each of six animals. One strip was not stimulated and was flash-frozen in relaxing solution for baseline rMLC phosphorylation measurements. Another strip was exposed to 0.3 µM free Ca 2ϩ for 25 min before freezing. The remaining three strips were first exposed to 0.3 µM free Ca 2ϩ alone for 10 min and then to 0.3 µM free Ca 2ϩ containing one of three PDBu concentrations (0.01, 1, or 10 µM) for 15 min before freezing.
Effect of PDBu on the relationship between [Ca 2ϩ ], rMLC phosphorylation, and isometric force. This protocol was conducted to establish the relationship between rMLC phosphorylation and isometric force induced by various [Ca 2ϩ ] in the presence and absence of PDBu. For isometric force measurements, four permeabilized CTSM strips were prepared from each of six dogs. Two strips were contracted with 0.6 µM free Ca 2ϩ , one in the absence and one in the presence of 1 µM PDBu; the other two strips were contracted with 1 or 10 µM free Ca 2ϩ alone. Isometric force was recorded for 15 min. At the concentrations of free Ca 2ϩ and PDBu chosen, contractions remain stable for the time course of the experimental protocol.
For rMLC phosphorylation measurements, nine permeabilized CTSM strips were prepared from each of six dogs. One strip was not stimulated and was flash-frozen in relaxing solution for baseline rMLC phosphorylation measurements. The remaining eight muscle strips were stimulated with varying free Ca 2ϩ concentrations (0.3, 0.6, 1, or 10 µM), four in the presence and four in the absence of 1 µM PDBu for 15 min before freezing. [Ca 2ϩ ]. This protocol investigated whether PKC inhibitors could attenuate the PDBu-induced increases in Ca 2ϩ sensitivity and rMLC phosphorylation. For isometric force measurements, we investigated whether calphostin C, chelerythrine chloride, PSSI, or staurosporine could prevent or reverse PDBu-induced increases in Ca 2ϩ sensitivity. Four sets of two permeabilized CTSM strips were prepared and studied concomitantly, one for each inhibitor from each of five dogs. The two strips were superfused with relaxing solution alone (control) or in the presence (preincubation) of either 1 µM calphostin C, 40 µM chelerythrine chloride, 3 µM PSSI, or 0.1 µM staurosporine for 15 min. Both strips were contracted with 0.3 µM free Ca 2ϩ , one in the absence (control) and one in the presence (preincubation) of the PKC inhibitor for 10 min. Then, both strips were contracted with 0.3 µM free Ca 2ϩ containing 1 µM PDBu in the absence (control) or presence (preincubation) of the PKC inhibitors for an additional 15 min, and isometric force responses were measured. To determine whether any of the four PKC inhibitors could reverse the increase in Ca 2ϩ sensitivity induced by PDBu, the control CTSM strip was exposed to either 1 µM calphostin C, 40 µM chelerythrine chloride, 3 µM PSSI, or 0.1 µM staurosporine 15 min after the addition of 1 µM PDBu to solutions containing 0.3 µM free Ca 2ϩ (Fig. 1) . The isometric force in the presence of the PKC inhibitor was measured and compared with the value immediately before the addition of each inhibitor.
Effect of PKC inhibitors on PDBu-induced increases in isometric force and rMLC phosphorylation at a constant submaximal
For rMLC phosphorylation measurements, nine permeabilized CTSM strips were prepared from each of six dogs. For these experiments, only calphostin C and PSSI were studied, since they are the more selective PKC inhibitors acting on the regulatory site of PKC (17, 22) . To exclude an effect of these two PKC inhibitors on baseline rMLC phosphorylation measurements, three strips were exposed to relaxing solution alone (control) or to relaxing solution containing either 1 µM calphostin C or 3 µM PSSI for 15 min before freezing. To exclude a nonspecific effect of the PKC inhibitors on increases in rMLC phosphorylation induced by free Ca 2ϩ alone, three strips were stimulated with 0.6 µM free Ca 2ϩ alone or 0.6 µM free Ca 2ϩ containing either 1 µM calphostin C or 3 µM PSSI for 15 min before freezing. One of the remaining three strips was stimulated with 0.6 µM free Ca 2ϩ containing 1 µM PDBu for 15 min; the other two strips were preincubated in relaxing solution containing either 1 µM calphostin C or 3 µM PSSI for 15 min and then exposed to 0.6 µM free Ca 2ϩ containing 1 µM PDBu in the presence of 1 µM calphostin C or 3 µM PSSI for 15 min before freezing.
Materials
The polyclonal affinity-purified rabbit anti-rMLC 20-kDa antibody was a generous gift of Dr. Susan J. Gunst, Department of Physiology and Biophysics, Indiana University School of Medicine, Indianapolis, IN. ATP, disodium salt, was purchased from Research Organics (Cleveland, OH). TCA was purchased from Fisher Scientific (Fair Lawn, NJ). The PKC inhibitor PSSI was purchased from Boehringer Mannheim Biochemica (Indianapolis, IN). All other drugs and chemicals were purchased from Sigma Chemical (St. Louis, MO). A-23187, calphostin C, chelerythrine chloride, PDBu, and staurosporine were dissolved in DMSO; in all experimental solutions, the final concentration of DMSO did not exceed 0.1%. At this concentration, DMSO had no effect on isometric force or rMLC phosphorylation induced by free Ca 2ϩ alone (data not shown). All other drugs and chemicals were prepared in distilled water.
Statistical Analysis
Data are expressed as means Ϯ SE for a minimum of five experiments; n represents the number of dogs. For multiple comparisons, a one-way ANOVA was performed. Differences in rMLC phosphorylation levels and isometric force were evaluated by Student's t-test for paired and unpaired data as appropriate. To determine whether PDBu altered the level of rMLC phosphorylation required to produce a given amount of isometric force, rMLC phosphorylation was calculated for the amount of isometric force during stimulation with PDBu using a nonlinear polynomial regression of the measured control isometric force values induced by free Ca 2ϩ alone. This interpolated rMLC phosphorylation value was then compared with the measured rMLC phosphorylation value during PDBu stimulation by paired Student's t-test. A P value Յ0.05 was required for statistical significance.
RESULTS
Time-Dependent Effect of PDBu on rMLC Phosphorylation
Stimulation with 0.3 µM free Ca 2ϩ alone for 10 min significantly increased rMLC phosphorylation above baseline (from 15.7 Ϯ 2.0 to 22.1 Ϯ 2.6%). This Ca 2ϩ -induced increase in rMLC phosphorylation remained stable over the time course of the protocol (10 min, 22.1 Ϯ 2.6%; 25 min, 21.9 Ϯ 2.0%). Compared with 0.3 µM free Ca 2ϩ alone, activation with 1 µM PDBu significantly increased rMLC phosphorylation after 5 min of PDBu exposure (from 22.1 Ϯ 2.6 to 31.1 Ϯ 2.78%), an increase that was sustained over the time course of the experiment (Fig. 2) .
Concentration-Dependent Effect of PDBu on rMLC Phosphorylation
Stimulation with 0.3 µM free Ca 2ϩ alone for 10 and 25 min increased rMLC phosphorylation above baseline (from 18.2 Ϯ 2.3 to 23.8 Ϯ 2.3 and 21.9 Ϯ 1.8%, respectively). Activation with 0.3 µM free Ca 2ϩ for 10 min followed by 0.3 µM free Ca 2ϩ containing 1 or 10 µM PDBu for 15 min significantly increased rMLC phosphorylation above baseline values and rMLC phosphorylation values produced by 0.3 µM free Ca 2ϩ alone (from 21.9 Ϯ 1.8 to 31.4 Ϯ 2.5 and 33.4 Ϯ 3.4%, respectively). PDBu (0.01 µM) did not significantly increase rMLC phosphorylation values above rMLC phosphorylation (Fig. 3) .
Effect of PDBu on the Relationship Between [Ca 2ϩ ], rMLC Phosphorylation, and Isometric Force
Ca 2ϩ caused a significant, concentration-dependent increase in both isometric force (Table 1 ) and rMLC phosphorylation (Fig. 4) . The addition of 1 µM PDBu to solutions containing 0.6 µM free Ca 2ϩ significantly enhanced Ca 2ϩ sensitivity, increasing the isometric force (Table 1) . Likewise, 1 µM PDBu significantly increased rMLC phosphorylation above that produced by each of the four free Ca 2ϩ concentrations (Fig. 4) . There was no significant difference in the magnitude of 4 . Effect of various free Ca 2ϩ concentrations (0.3, 0.6, 1, and 10 µM) on rMLC phosphorylation in absence and presence of 1 µM PDBu in ␤-escin-permeabilized canine trachea smooth muscle. Compared with baseline rMLC phosphorylation level, activation with free Ca 2ϩ alone caused a significant increase in rMLC phosphorylation at each free Ca 2ϩ concentration (# P Յ 0.05). Activation with free Ca 2ϩ solutions containing 1 µM PDBu significantly increased rMLC phosphorylation compared with free Ca 2ϩ alone at each Ca 2ϩ concentration (* P Յ 0.05). There was no significant difference in magnitude of PDBu-induced increase in rMLC phosphorylation between different Ca 2ϩ concentrations. Values are means Ϯ SE; n ϭ 6 dogs. Force measurements are expressed as percent relative to maximal force produced by 10 µM free Ca 2ϩ determined in same strip before experiment. PDBu, phorbol 12,13-dibutyrate.
the PDBu-induced increase in rMLC phosphorylation between the Ca 2ϩ concentrations (Fig. 4) .
PDBu significantly altered the relationship between rMLC phosphorylation and isometric force. The increase in isometric force induced by 0.6 µM free Ca 2ϩ containing 1 µM PDBu was 51.1 Ϯ 5.4% of maximal isometric force, and the corresponding rMLC phosphorylation value measured was 39.1 Ϯ 4.4%. On the basis of nonlinear interpolation of the isometric force induced by free Ca 2ϩ alone, the corresponding increase in rMLC phosphorylation was significantly greater than expected (measured rMLC phosphorylation, 39.1 Ϯ 4.4% vs. expected rMLC phosphorylation, 34.2 Ϯ 3.6%). Thus PDBu increased both isometric force and rMLC phosphorylation at a constant [Ca 2ϩ ], but the amount of isometric force at this level of rMLC phosphorylation was less than predicted based on the relationship between rMLC phosphorylation and isometric force obtained during stimulation with Ca 2ϩ alone (Fig. 5) . Table 2 shows the effect of preincubation with 1 µM calphostin C, 40 µM chelerythrine chloride, 3 µM PSSI, and 0.1 µM staurosporine on isometric force induced by 0.3 µM free Ca 2ϩ alone or by 0.3 µM free Ca 2ϩ containing 1 µM PDBu. Staurosporine at concentrations Ͼ0.1 µM was not studied, since these concentrations attenuated isometric force induced by 0.3 µM free Ca 2ϩ alone (data not shown). This finding indicates that staurosporine at high concentrations has nonspecific effects on isometric force other than inhibiting PKC. None of the PKC inhibitors significantly affected the increase in isometric force induced by 0.3 µM free Ca 2ϩ alone, nor did they prevent or attenuate the increase in isometric force induced by PDBu at a constant submaximal [Ca 2ϩ ] (Fig. 1) . Table 3 shows the effect of each of the four PKC inhibitors (treatment) when added to strips in which Ca 2ϩ sensitization was induced by 1 µM PDBu at 0.3 µM free Ca 2ϩ (control). None of the PKC inhibitors reversed the PDBu-induced increase in Ca 2ϩ sensitivity.
Effect of PKC Inhibitors on PDBu-Induced Increases in Isometric Force and rMLC Phosphorylation at a Constant Submaximal [Ca 2ϩ ]
Neither calphostin C nor PSSI had an effect on baseline rMLC phosphorylation (control, 11.1 Ϯ 1.2%; calphostin C, 10.3 Ϯ 0.6%; PSSI, 9.9 Ϯ 1.0%) or rMLC phosphorylation induced by 0.6 µM free Ca 2ϩ alone (control, 20.3 Ϯ 3.2%; calphostin C, 18.8 Ϯ 3.0%; PSSI, 20.4 Ϯ 2.8%). Table 4 shows the effect of preincubation with calphostin C and PSSI on rMLC phosphorylation levels induced by 0.6 µM free Ca 2ϩ and 1 µM PDBu. There was no significant difference between rMLC phosphorylation levels induced by 0.6 µM free Ca 2ϩ alone and 0.6 µM free Ca 2ϩ containing 1 µM PDBu in the presence of the PKC inhibitors, indicating that Isometric force measurements were normalized to isometric force determined in same tissues induced by 10 µM free Ca 2ϩ alone and expressed as a percentage of this maximal isometric force development. On the basis of nonlinear interpolation of isometric force induced by free Ca 2ϩ alone, corresponding increase in rMLC phosphorylation in response to 0.6 µM free Ca 2ϩ containing 1 µM PDBu was significantly greater than expected. Thus PDBu increased both isometric force and rMLC phosphorylation at a constant intracellular [Ca 2ϩ ], but amount of isometric force developed at this level of rMLC phosphorylation was less than predicted based on relationship between rMLC and isometric force obtained during stimulation with free Ca 2ϩ alone. Values are means Ϯ SE; n ϭ 5 dogs. Isometric force measurements are expressed as percent relative to maximal isometric force induced by 10 µM free Ca 2ϩ . Ca 2ϩ sensitization was induced with 1 µM PDBu (EC 90 ) and 0.3 µM free Ca 2ϩ (control). Concentrations of PKC inhibitors (treatment) used were as follows: 1 µM calphostin C, 40 µM chelerythrine chloride, 3 µM PSSI, and 0.1 µM staurosporine. 
DISCUSSION
The major findings of this study in ␤-escin-permeabilized CTSM are as follows: 1) stimulation with the phorbol ester PDBu increases rMLC phosphorylation via activation of PKC; 2) this increase in rMLC phosphorylation does not mediate PDBu-induced increases in Ca 2ϩ sensitivity; and 3) the PDBu-induced increase in Ca 2ϩ sensitivity does not involve the activation of PKC at a constant submaximal [Ca 2ϩ ].
In vascular (11, 18) and colonic (27) smooth muscle, PKC is thought to in part mediate agonist-induced Ca 2ϩ sensitization. Stimulation with membrane receptor agonists is proposed to result in phosphorylation of the 20-kDa rMLC via a GTP-dependent activation of phospholipase C. Phospholipase C hydrolyzes phosphatidylinositol 4,5-bisphosphate and phosphatidylcholine, producing inositol 1,4,5-trisphosphate and diacylglycerol (DAG). By binding to the regulatory domain of PKC, DAG and its analogs, such as 1-oleoyl-2-acetyl-snglycerol (OAG) (29) , can activate conventional and novel PKC isoforms. Once activated, PKC may directly or indirectly inhibit the rMLC phosphatases (23) . Inhibition of rMLC phosphatases that dephosphorylate rMLC is thought to be the major mechanism of agonistinduced Ca 2ϩ sensitization in smooth muscle. Phorbol esters such as PDBu activate PKC by binding to the regulatory domain of PKC (29) and thus inhibiting rMLC phosphatases (23), increasing rMLC phosphorylation and isometric force at a constant submaximal [Ca 2ϩ ] i (21) . Further evidence for a role of PKC in Ca 2ϩ sensitization has been provided by using various pharmacological PKC inhibitors to reverse or prevent phorbol ester-induced contractions in intact (28) and permeabilized vascular (11, 18) and permeabilized vas deferens (10) smooth muscle preparations. However, the involvement of PKC in mediating Ca 2ϩ sensitivity is controversial, depending on the species, the type of smooth muscle, and the kind of agonist used. Stimulation of various smooth muscle types with physiological agonists like ACh (26), norepinephrine (10), prostaglandin F 2␣ (16) as well as stimulation with AlF 4 Ϫ (10) is not inhibited by downregulation of PKC or by a variety of PKC inhibitors.
In airway smooth muscle, the role of PKC in mediating contraction is also unclear. The PKC isoforms present in CTSM have been identified and include the conventional Ca 2ϩ -dependent isoenzymes ␤I and ␤II, the novel Ca 2ϩ -independent isoenzymes ␦, ⑀, and , and the atypical isoenzyme (8) . The atypical PKC isoenzyme is insensitive to stimulation with PDBu, and its activation is independent of Ca 2ϩ , DAG, and phospholipid (7) . During contraction of CTSM, an agonistinduced translocation of PKC from the cytosol to membrane fractions has been described, implying a functional change from the inactive to the active, membrane-bound form of PKC (33) (5) . These results raise the question of how PDBu increases Ca 2ϩ sensitivity in permeabilized CTSM, if PKC does not contribute to Ca 2ϩ sensitization produced by the physiological membrane receptor agonist ACh.
In this study, stimulation with PDBu induced a concentration-dependent, sustained increase in rMLC phosphorylation at constant [Ca 2ϩ ]. However, there are two lines of evidence that the observed increase in rMLC phosphorylation may not be responsible for the increase in isometric force at a constant [Ca 2ϩ ]. First, based on phosphopeptide mapping and sequence analysis in bovine tracheal tissue, Kamm et al. (19) showed that PDBu-induced activation of PKC mainly results in rMLC phosphorylation at the serine-1, serine-2, and threonine-9 residues (19). In contrast, in vascular smooth muscle, PDBu-induced PKC activation phosphorylates rMLC at serine-19 and threonine-18 only (11). It is thought that phosphorylation of the rMLC at sites other than serine-19 and threonine-18 does not to contribute to contraction; in fact, it has been shown that the additional phosphorylation of rMLC by PKC at threonine-9 attenuates the increase in Mg 2ϩ -ATPase activity associated with MLCK phosphorylation at serine-19 (19) . In addition, phosphorylation of bovine tracheal myosin by PKC does not affect actin sliding velocity in an in vitro motility assay when the myosin (32) . In the current study, rMLC phosphorylation measurements performed detect total amounts of unphosphorylated and phosphorylated rMLC; phosphopeptide mapping to determine the site of phosphorylation was not performed. However, based on these previous studies, we speculate that the observed disparity in isometric force and expected level of rMLC phosphorylation during activation with PDBu at a constant submaximal [Ca 2ϩ ] (Fig. 5 ) reflects phosphorylation by PDBu of rMLC sites that do not contribute to increases in isometric force. In support of this hypothesis, Gerthoffer and co-workers (12, 13) described a PDBu-induced increase in rMLC phosphorylation under some conditions in intact CTSM without a corresponding increase in isometric force.
Second, by using the more specific PKC inhibitors calphostin C and PSSI, we demonstrated that the PDBu-induced increase in rMLC is indeed mediated by activation of PKC, yet these inhibitors did not affect PDBu-induced Ca 2ϩ sensitization. To block the effect of PDBu on conventional and novel PKC isoforms (31) present in CTSM, two different classes of distinct pharmacological PKC inhibitors were utilized. There are two possible targets for PKC inhibitors within PKC: a catalytic domain exhibiting substantial homology with other serine-and threonine-specific kinases and tyrosine-specific kinases (30) , and a regulatory domain functioning as the binding site for DAG and its analogs. Staurosporine and chelerythrine chloride, both acting on the catalytic domain, are considered to be fairly nonspecific. Furthermore, staurosporine in concentrations higher than 0.1 µM attenuated isometric force induced by free Ca 2ϩ alone (data not shown). Calphostin C and the pseudosubstrate inhibitor PSSI (directed toward a 19-amino acid consensus sequence for PKC) are more selective and both act on the regulatory site (30) . All four PKC inhibitors were used in considerable excess of published IC 50 values (5); these concentrations are thought to specifically inhibit PKC activity (26) , whereas higher concentrations also significantly attenuate other kinases, e.g., MLCK (6); we observed evidence of this behavior at high concentrations of staurosporine (data not shown).
Recently, mechanisms in addition to rMLC phosphorylation have been proposed to mediate the effect of phorbol esters in smooth muscle through activation of PKC. In vitro studies have shown that the actinbinding proteins caldesmon and calponin are PKC substrates in solution, and phorbol esters, via activation of PKC isoforms, suppress calponin-and caldesmonmediated inhibition of actomyosin Mg 2ϩ -ATPase (1, 24) . Both of these proteins can be phosphorylated during smooth muscle contraction (1, 14, 24) , but the physiological significance of this phosphorylation and the role of PKC in this process are unclear. The lack of effect of the PKC inhibitors on PDBu-induced calcium sensitization in our study does not support a role for a PKC-mediated process involving these actin-binding proteins.
The findings of this study suggest that PDBu increases Ca 2ϩ sensitivity in permeabilized CTSM by activating an intracellular signal transduction pathway other than PKC. The fact that calphostin C and PSSI blocked PDBu-induced increases in rMLC phosphorylation without affecting isometric force demonstrate that PDBu can, under these circumstances, increase Ca 2ϩ sensitivity by a mechanism that does not involve activation of PKC. It can, however, not be excluded that activation of PKC with PDBu could have induced a small increase in serine-19 and threonine-18 rMLC phosphorylation in the presence of the PKC inhibitors, an increase that could not be detected with our methods (Table 4) . Several intracellular targets for PDBu other than PKC have recently been described. Different classes of proteins containing a single homologous cysteine-rich motif such as n-chimaerin (2) and Unc-13 (20) are high-affinity phorbol ester receptors whose binding affinities are similar to that of PKC. Although their role in smooth muscle contraction is unknown, the COOH-terminal domain of chimaerins is thought to perform as a GTPase-activating protein for the small GTP-binding protein p21 rac (20) . Furthermore, it has been demonstrated in permeabilized vascular smooth muscle that PDBu can phosphorylate a still unidentified 25-kDa protein or protein subunit (9) . The exploration of these novel mechanisms by which PDBu might increase Ca 2ϩ sensitization is beyond the scope of the current study.
In summary, PDBu caused an increase in Ca 2ϩ sensitivity at a constant submaximal [Ca 2ϩ ] in ␤-escinpermeabilized CTSM that was accompanied by an increase in rMLC phosphorylation. Although the increase in rMLC phosphorylation was inhibited by calphostin C and PSSI, none of the pharmacological PKC inhibitors prevented or reversed PDBu-induced increases in isometric force. These results suggest that PDBu increases rMLC phosphorylation via activation of PKC, but this increase in rMLC phosphorylation is not the mechanism by which PDBu increases isometric force at a constant submaximal [Ca 2ϩ ] in CTSM. Furthermore, our findings give evidence of an as yet unidentified pathway of phorbol ester-induced Ca 2ϩ sensitization other than activation of PKC and rMLC phosphorylation.
